Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CHK1 is a master regulator of the DNA damage response (DDR) and cell cycle checkpoints in eukaryotic cells. It plays essential roles in initiating and maintaining cell cycle arrest, stabilizing stalled replication forks, and phosphorylating key regulators like CDK1. CHK1 is a validated clinical trial target with particular relevance in oncology, as its inhibition can sensitize p53-deficient cancer cells to genotoxic therapies.
CHK1 activation primarily occurs via phosphorylation by the upstream regulatory kinase ATR. Upon activation, CHK1 phosphorylates downstream substrates involved in cell cycle control. In unperturbed cycles, it regulates normal progression through S phase, G2/M transition, and M phase. In response to genotoxic stress or DNA damage, it triggers checkpoints that halt the cell cycle for repair processes. If repair fails or damage is excessive, it can lead to programmed cell death (apoptosis).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Checkpoint kinase 1 (CHK1).